

## **PEGTIBATINASE, AN INVESTIGATIONAL ENZYME REPLACEMENT THERAPY FOR THE TREATMENT OF CLASSICAL HOMOCYSTINURIA: INITIAL RESULTS FROM THE PHASE 1/2 COMPOSE STUDY**

**Harvey L. Levy**, Janet Thomas, Can Ficicioglu, Melissa Lah, Jaya Ganesh, Marcia Sellos-Moura, Erez M. Bublil, Liz Wilkening, Jalé Güner, Ying Chen, Feriandas Greblikas, Sagar A. Vaidya

Cystathionine beta synthase (CBS)-deficient homocystinuria (HCU), also known as classical HCU, is a rare autosomal recessive disorder caused by pathogenic variants in the *CBS* gene. CBS is a critical enzyme required for the processing of homocysteine (Hcy), a key intermediate in the metabolism of methionine through the transsulfuration pathway. CBS deficiency causes toxic accumulation of Hcy which results in the clinical manifestations of HCU. These primarily affect cardiovascular, skeletal, neurologic, and ocular organ systems, with thromboembolism being the major cause of early mortality. The current standard-of-care for HCU includes a methionine-restricted diet, vitamin B<sub>6</sub>, and betaine. Despite these treatments, many patients with HCU are unable to sufficiently reduce their Hcy levels and ultimately develop the clinical manifestations associated with HCU. Thus, there exists a significant unmet medical need for novel disease-modifying treatments for HCU.

Pegtibatinase is an engineered pegylated form of human CBS that is currently being studied as the first-in-class investigational enzyme replacement therapy for HCU. COMPOSE (NCT 03406611) is a double-blind, randomized, placebo-controlled, Phase 1/2 dose escalation study with 4 subjects per cohort, randomized at 3:1 for active drug versus placebo. Study objectives include assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of pegtibatinase given subcutaneously once or twice weekly. Key eligibility criteria were confirmed diagnosis of HCU with total plasma Hcy level  $\geq 80$  micromoles/L and age 12-65 years. The study began in 2019 and 19 subjects have been enrolled across five dose cohorts at the following doses: 0.33mg/kg weekly, 0.66mg/kg weekly, 1.0mg/kg weekly, 1.0mg/kg twice weekly, and 1.5mg/kg twice weekly. After each dose cohort completed the first 6 weeks of treatment, an independent data monitoring committee reviewed the unblinded safety data prior to enrollment of the next higher dose cohort. A planned unblinded analysis was conducted after the last subject in Cohort 5 completed 12 weeks of double-blind treatment. Results of the COMPOSE study including incidence of adverse events, immunogenicity, and treatment effect of pegtibatinase on total plasma Hcy along with other related metabolites will be presented.

Word count: 331 (limit <500)

Due Date: 30 NOV 2021

(see author affiliations and guidelines below)

**Author Affiliations and contributions**<sup>[JG1]</sup>:

Harvey L. Levy  
Boston Children's Hospital  
Contributed to the design and interpretation of the study, participated in the trial as clinical site

Janet Thomas  
University of Colorado School of Medicine and the Children's Hospital Colorado  
Contributed to the design and interpretation of the study, participated in the trial as clinical site

Can Ficicioglu  
Children's Hospital of Philadelphia  
Contributed to the design and interpretation of the study, participated in the trial as clinical site

Melissa Lah  
Indiana University School of Medicine  
Participated in the trial as clinical site

Jaya Ganesh  
Icahn School of Medicine at Mount Sinai  
Participated in the trial as clinical site

Marcia Sellos-Moura  
Travere Therapeutics  
Contributed to the design and interpretation of the study, and writing of the abstract

Erez M. Bublil  
Travere Therapeutics  
Contributed to the design and interpretation of the study, and writing of the abstract

Elizabeth Wilkening  
Travere Therapeutics  
Contributed to the design and interpretation of the study

Jalé Güner  
Travere Therapeutics  
Contributed to the design and interpretation of the study, and writing of the abstract

Ying Chen  
Travere Therapeutics

Contributed to the design and interpretation of the study, analysis of the clinical data

Ferianas Greblikas

Travere Therapeutics

Contributed to the design and interpretation of the study, analysis of the clinical data, and writing of the abstract

Sagar A. Vaidya

Travere Therapeutics

Contributed to the design and interpretation of the study, analysis of the clinical data, and writing of the abstract

#### **GUIDELINES FOR ABSTRACT FORMATTING:**

- We recommend 10 point 'Times' font.
- Use capitalized font for the title paragraph and normal font for the authors/affiliations and body paragraphs (as below).
- Within the body of the abstract, indentation is not required. Headers (such as "Objectives"/"Background", "Methods"/"Materials", "Results", "Conclusions") are suggested but not required.
- To be certain the size will be right, you can set the size of the printed region on the working page to **5.8 inches wide and 10. inches high** (i.e. a 6.8"W X11."H page with 0.5" margins all around), the layout will simulate that of a single column of the two-column format published in the journal, and the abstract will fit in about 3/4 of a full column in the journal if it does not wrap to a second page.
- You may download an abstract [template for Microsoft Word](#) which has those settings. Simply paste your content, save, and copy from that to the upload software.
- There is no fixed size limitation, but we suggest limiting to <500 words. The **maximum size of the uploaded files is 1,000 kb**. Please contact us ([abstracts@simd.org](mailto:abstracts@simd.org)) if you require special arrangements.
- **Submit abstracts on-line, not as hardcopy**. But, you do need to forward the non-exclusive [license agreement](#) showing that all authors agree to publishing the abstract (only needs to be signed by one author- mail, scan/email, or fax to [Leslie Lublink](#)).
- All abstracts accepted will be published in the journal *Molecular Genetics and Metabolism*.
- Follow instructions in the [On-Line Abstract Submission](#) software.